← Browse by Condition
Medical Condition
b cell malignancies
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
NCT05432882 Phase 1, Phase 2
Recruiting
CD19/22 Bi-specific CAR-T Cell Therapy
Enrollment
60 pts
Location
China
Sponsor
Shenzhen Geno-Immune Medical I...
NCT07135466 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Enrollment
50 pts
Location
Israel
Sponsor
Sheba Medical Center